I am a
Home I AM A Search Login

Papers of the Week

2023 Feb 03


Cost Effectiveness of Difelikefalin Compared to Standard Care for Treating Chronic Kidney Disease Associated Pruritus (CKD-aP) in People with Kidney Failure Receiving Haemodialysis.


Thokala P, Hnynn Si P E, Hernandez Alava M, Sasso A, Schaufler T, Soro M, Fotheringham J
Pharmacoeconomics. 2023 Feb 03.
PMID: 36735201.


Chronic kidney disease-associated pruritus (CKD-aP) is associated with an increased risk of depression, poor sleep and reduced health-related quality of life. Two phase III studies (KALM-1 and KALM-2) of difelikefalin showed reduced CKD-aP severity and improved itch-related health-related quality of life in patients with moderate and severe CKD-aP receiving haemodialysis for kidney failure.